William Guy
Psychiatry · Southfield, MINPI 1295748101
Payments from drug & device makers
Across 1,072 payments — averaging $524.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$273K
- Teva Pharmaceuticals USA, Inc.$105K
- Otsuka America Pharmaceutical, Inc.$75K
- Axsome Therapeutics, Inc.$46K
- Alkermes, Inc.$33K
- Vanda Pharmaceuticals Inc.$19K
- plus $12K from 25 others
What the payments were for
- Consulting fees$32,1106%
- Speaking & faculty fees$451,82280%
- Travel & lodging$55,76510%
- Food & beverage$22,3114%
- Education$260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 363 | $272,916 |
| Teva Pharmaceuticals USA, Inc. | 138 | $105,232 |
| Otsuka America Pharmaceutical, Inc. | 138 | $74,611 |
| Axsome Therapeutics, Inc. | 49 | $45,818 |
| Alkermes, Inc. | 69 | $32,934 |
| Vanda Pharmaceuticals Inc. | 38 | $18,639 |
| Sunovion Pharmaceuticals Inc. | 41 | $7,723 |
| Johnson & Johnson | 39 | $578 |
| Corium, LLC | 29 | $464 |
| Takeda Pharmaceuticals U.S.A., Inc. | 30 | $461 |
| Neurocrine Biosciences, Inc. | 19 | $388 |
| Avanir Pharmaceuticals, Inc. | 20 | $373 |
| AbbVie(2 entities) | 26 | $348 |
| Idorsia Pharmaceuticals US Inc | 13 | $274 |
| Lundbeck LLC | 14 | $238 |
| Livanova USA, Inc. | 5 | $198 |
| Neuronetics, Inc. | 3 | $153 |
| Indivior Inc. | 9 | $150 |
| Tris Pharma Inc | 5 | $83 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $81 |
| Merck | 4 | $67 |
| Bausch Health US, LLC | 4 | $66 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Supernus Pharmaceuticals, Inc. | 2 | $38 |
| Eisai Inc. | 2 | $34 |
| Noven Therapeutics, LLC | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $19 |
| Brainsway USA Inc | 1 | $18 |
| Neos Therapeutics, LP | 1 | $17 |
| OWP Pharmaceuticals, Inc. | 2 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$267,668
- ARISTADA$115,076
- REXULTI$72,443
- AUSTEDO$49,660
- Auvelity$45,355
- Austedo XR$35,678
- ARISTADA INITIO$28,769
- Fanapt$18,264
- UZEDY$15,996
- LATUDA$7,257
- NEUROSTAR TMS THERAPY$123
- NUEDEXTA$122
- INGREZZA$122
- VNS - Symmetry$115
How this compares
$562,034 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FanaptIloperidone | 12 | $25,570 |
| RexultiBrexpiprazole | 14 | $18,358 |
| Aripiprazole | 16 | $5,163 |
| Lurasidone Hcl | 44 | $4,619 |
| Vilazodone Hcl | 45 | $4,502 |
| ConcertaMethylphenidate Hcl | 11 | $4,339 |
| Quetiapine Fumarate | 120 | $3,640 |
| Fluphenazine Hcl | 12 | $3,517 |
| Fluvoxamine Maleate | 26 | $2,327 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 33 | $2,288 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 22 | $1,831 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 43 | $1,776 |
| Gabapentin | 94 | $1,565 |
| Bupropion XlBupropion Hcl | 73 | $1,410 |
| Pregabalin | 44 | $1,013 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Vanda Pharmaceuticals Inc.Fanapt | $18,639 | $25,57012 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $74,611 | $18,35814 claims |
| Johnson & JohnsonConcerta | $578 | $4,33911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,166 psychiatry providers in Michigan.
Other psychiatry in Southfield
- Farhad AmiriSouthfield$40K
- Andreas SidiropoulasDetroit$2.8M
- Joel YoungRochester Hills$1.9M
- Welton WashingtonYpsilanti$1.4M
- Rajaprabhakaran RajarethinamAnn Arbor$1.2M
- Eric AchtyesGrand Rapids$705K
- Manzar RajputMonroe$612K
- Brian MickeyAnn Arbor$490K
- Sagar ParikhAnn Arbor$331K
- Robert LagrouClarkston$267K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.